Effects of glucocorticoids and interleukin-1β on expression and activity of aggrecanases in equine chondrocytes

American Journal of Veterinary Research

Volumn 71, Issue 2, 2010, Pages 176-185

  Busschers, Evita ^a,b   Holt, Jeff P ^a,c   Richardson, Dean W ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Veterinary Centre Someren   (Netherlands)

^c DREXEL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECANASE; COLLAGENASE 3; GLYCOSAMINOGLYCAN; INTERLEUKIN 1BETA; MESSENGER RNA; METALLOPROTEINASE; METALLOPROTEINASE ADAMTS 4; METALLOPROTEINASE ADAMTS 5; STROMELYSIN; TRIAMCINOLONE; UNCLASSIFIED DRUG;

ARTICLE; CADAVER; CARTILAGE CELL; CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HORSE; MUSCULOSKELETAL DISEASE; NONHUMAN; NORTHERN BLOTTING; NOSE CARTILAGE; PROTEIN EXPRESSION; SEPSIS; UPREGULATION; WESTERN BLOTTING;

ADAM PROTEINS; ANIMALS; CARTILAGE; CELLS, CULTURED; CHONDROCYTES; DEXAMETHASONE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCOCORTICOIDS; HORSES; INTERLEUKIN-1BETA; METALLOPROTEASES; TISSUE CULTURE TECHNIQUES; TRIAMCINOLONE;

EQUIDAE;

EID: 77249155723     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.71.2.176     Document Type: Article

References (62)

1. Lark MW, Gordy JT, Weidner JR, et al. Cell-mediated catabolism of aggrecan. Evidence that cleavage at the "aggrecanase" site (Glu373-Ala374) is a primary event in proteolysis of the interglobular domain. J Biol Chem 1995;270:2550-2556.
2. Fosang AJ, Last K, Maciewicz RA. Aggrecan is degraded by matrix metalloproteinases in human arthritis. Evidence that matrix metalloproteinase and aggrecanase activities can be independent. J Clin Invest 1996;98:2292-2299.
3. Arner EC, Hughes CE, Decicco CP, et al. Cytokine-induced cartilage proteoglycan degradation is mediated by aggrecanase. Osteoarthritis Cartilage 1998;6:214-228.
4. Little CB, Flannery CR, Hughes CE, et al. Aggrecanase versus matrix metalloproteinases in the catabolism of the interglobular domain of aggrecan in vitro. Biochem J 1999;344:61-68.
5. Struglics A, Larsson S, Pratta MA, et al. Human osteoarthritis synovial fluid and joint cartilage contain both aggrecanase- and matrix metalloproteinase-generated aggrecan fragments. Osteoarthritis Cartilage 2006;14:101-113.
6. Malfait AM, Liu RQ, Ijiri K, et al. Inhibition of ADAM-TS4 and ADAM-TS5 prevents aggrecan degradation in osteoarthritic cartilage. J Biol Chem 2002;277:22201-22208.
7. Sandy JD, Verscharen C. Analysis of aggrecan in human knee cartilage and synovial fluid indicates that aggrecanase (ADAMTS) activity is responsible for the catabolic turnover and loss of whole aggrecan whereas other protease activity is required for C-terminal processing in vivo. Biochem J 2001;358:615-626.
8. Tortorella MD, Burn TC, Pratta MA, et al. Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science 1999;284:1664-1666.
9. Abbaszade I, Liu RQ, Yang F, et al. Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family. J Biol Chem 1999;274:23443-23450.
10. Pratta MA, Tortorella MD, Arner EC. Age-related changes in aggrecan glycosylation affect cleavage by aggrecanase. J Biol Chem 2000;275:39096-39102.
11. Roughley PJ, Barnett J, Zuo F, et al. Variations in aggrecan structure modulate its susceptibility to aggrecanases. Biochem J 2003;375:183-189.
12. Tortorella MD, Arner EC, Hills R, et al. Alpha2-macroglobulin is a novel substrate for ADAMTS-4 and ADAMTS-5 and represents an endogenous inhibitor of these enzymes. J Biol Chem 2004;279:17554-17561.
13. Kashiwagi M, Tortorella M, Nagase H, et al. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J Biol Chem 2001;276:12501-12504.
14. Hashimoto G, Shimoda M, Okada Y. ADAMTS4 (aggrecanase-1) interaction with the C-terminal domain of fibronectin inhibits proteolysis of aggrecan. J Biol Chem 2004;279:32483-32491.
15. Kashiwagi M, Enghild JJ, Gendron C, et al. Altered proteolytic activities of ADAMTS-4 expressed by C-terminal processing (Erratum published in J Biol Chem 2004,279:22786). J Biol Chem 2004;279:10109-10119.
16. Gendron C, Kashiwagi M, Lim NH, et al. Proteolytic activities of human ADAMTS-5: comparative studies with ADAMTS-4. J Biol Chem 2007;282:18294-18306.
17. Gao G, Plaas A, Thompson VP, et al. ADAMTS4 (aggrecanase-1) activation on the cell surface involves C-terminal cleavage by glycosylphosphatidyl inositol-anchored membrane type 4-matrix metalloproteinase and binding of the activated proteinase to chondroitin sulfate and heparan sulfate on syndecan-1. J Biol Chem 2004;279:10042-10051.
18. Gao G, Westling J, Thompson VP, et al. Activation of the proteolytic activity of ADAMTS4 (aggrecanase-1) by C-terminal truncation. J Biol Chem 2002;277:11034-11041.
19. Bondeson J, Lauder S, Wainwright S, et al. Adenoviral gene transfer of the endogenous inhibitor IkappaBalpha into human osteoarthritis synovial fibroblasts demonstrates that several matrix metalloproteinases and aggrecanases are nuclear factor-kappaB-dependent. J Rheumatol 2007;34:523-533.
20. Tortorella MD, Malfait AM, Deccico C, et al. The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation (Erratum published in Osteoarthritis Cartilage 2002;10:82). Osteoarthritis Cartilage 2001;9:539-552.
21. Bau B, Gebhard PM, Haag J, et al. Relative messenger RNA expression profiling of collagenases and aggrecanases in human articular chondrocytes in vivo and in vitro. Arthritis Rheum 2002;46:2648-2657.
22. Flannery CR, Little CB, Hughes CE, et al. Expression of ADAMTS homologues in articular cartilage. Biochem Biophys Res Commun 1999;260:318-322.
23. Koshy PJ, Lundy CJ, Rowan AD, et al. The modulation of matrix metalloproteinase and ADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M: a time-course study using real-time quantitative reverse transcription-polymerase chain reaction. Arthritis Rheum 2002;46:961-967.
24. Pattoli MA, MacMaster JF, Gregor KR, et al. Collagen and aggrecan degradation is blocked in interleukin-1-treated cartilage expiants by an inhibitor of IkappaB kinase through suppression of metalloproteinase expression. J Pharmacol Exp Ther 2005;315:382-388.
25. East CJ, Stanton H, Golub SB, et al. ADAMTS-5 deficiency does not block aggrecanolysis at preferred cleavage sites in the chondroitin sulfate-rich region of aggrecan. J Biol Chem 2007;282:8632-6640.
26. Stewart MC, Fosang AJ, Bai Y, et al. ADAMTS5-mediated aggrecanolysis in murine epiphyseal chondrocyte cultures. Osteoarthritis Cartilage 2006;14:392-402.
27. Stanton H, Rogerson FM, East CJ, et al. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature 2005;434:648-652.
28. Glasson SS, Askew R, Sheppard B, et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis (Erratum published in Nature 2007;446:102). Nature 2005;434:644-648.
29. Glasson SS, Askew R, Sheppard B, et al. Characterization of and osteoarthritis susceptibility in ADAMTS-4-knockout mice. Arthritis Rheum 2004;50:2547-2558.
30. Song RH, Tortorella MD, Malfait AM, et al. Aggrecan degradation in human articular cartilage expiants is mediated by both ADAMTS-4 and ADAMTS-5. Arthritis Rheum 2007;56:575-585.
31. Reginato AM, Iozzo RV, Jimenez SA. Formation of nodular structures resembling mature articular cartilage in long-term primary cultures of human fetal epiphyseal chondrocytes on a hydrogel substrate. Arthritis Rheum 1994;37:1338-1349.
32. Farndale RW, Sayers CA, Barrett AJ. A direct spectrophotometric microassay for sulfated glycosaminoglycans in cartilage cultures. Connect Tissue Res 1982;9:247-248.
33. Hughes CE, Little CB, Caterson B. Measurement of aggrecanase-generated interglobular domain catabolites in the medium and
34. extracts of cartilage expiants using Western blot analysis. Methods Mol Biol 2003;225:89-98.
35. Will H, Dettloff M, Bendzko P, et al. A quantitative assay for aggrecanase activity. J Biomol Tech 2005;16:459-472.
36. Little CB, Hughes CE, Curtis CL, et al. Matrix metalloproteinases are involved in C-terminal and interglobular domain processing of cartilage aggrecan in late stage cartilage degradation. Matrix Biol 2002;21:271-288.
37. Pratta MA, Scherle PA, Yang G, et al. Induction of aggrecanase 1 (ADAM-TS4) by interleukin-1 occurs through activation of constitutively produced protein. Arthritis Rheum 2003;48:119-133.
38. Naito S, Shiomi T, Okada A, et al. Expression of ADAMTS4 (aggrecanase-1) in human osteoarthritic cartilage. Pathol Int 2007;57:703-711.
39. Celeste C, Ionescu M, Robin Poole A, et al. Repeated intraarticular injections of triamcinolone acetonide alter cartilage matrix metabolism measured by biomarkers in synovial fluid. J Orthop Res 2005;23:602-610.
40. Frisbie DD, Kawcak CE, Trotter GW, et al. Effects of triamcinolone acetonide on an in vivo equine osteochondral fragment exercise model. Equine Vet J 1997;29:349-359.
41. Todhunter RJ, Fubini SL, Wootton JA, et al. Effect of methylprednisolone acetate on proteoglycan and collagen metabolism of articular cartilage expiants. J Rheumatol 1996;23:1207-1213.
42. MacLeod JN, Fubini SL, Gu DN, et al. Effect of synovitis and corticosteroids on transcription of cartilage matrix proteins. Am J Vet Res 1998;59:1021-1026.
43. Todhunter RJ, Fubini SL, Vernier-Singer M, et al. Acute synovitis and intra-articular methylprednisolone acetate in ponies. Osteoarthritis Cartilage 1998;6:94-105.
44. Frisbie DD, Nixon AJ. Insulin-like growth factor 1 and corticosteroid modulation of chondrocyte metabolic and mitogenic activities in interleukin 1-conditioned equine cartilage (Erratum published in Am J Vet Res 1997;58:701). Am J Vet Res 1997;58:524-530.
45. Murphy DJ, Todhunter RJ, Fubini SL, et al. The effects of methylprednisolone on normal and monocyte-conditioned medium-treated articular cartilage from dogs and horses. Vet Surg 2000;29:546-557.
46. Verschure PJ, van der Kraan PM, Vitters EL, et al. Stimulation of proteoglycan synthesis by triamcinolone acetonide and insulin-like growth factor 1 in normal and arthritic murine articular cartilage. J Rheumatol 1994;21:920-926.
47. van der Kraan PM, Vitters EL, Postma NS, et al. Maintenance of the synthesis of large proteoglycans in anatomically intact murine articular cartilage by steroids and insulin-like growth factor I. Ann Rheum Dis 1993;52:734-741.
48. Dechant JE, Baxter GM, Frisbie DD, et al. Effects of dosage titration of methylprednisolone acetate and triamcinolone acetonide on interleukin-1- conditioned equine articular cartilage explants in vitro. Equine Vet J 2003;35:444-450.
49. Richardson DW, Dodge GR. Dose-dependent effects of corticosteroids on the expression of matrix-related genes in normal and cytokine-treated articular chondrocytes. Inflamm Res 2003;52:39-49.
50. Mengshol JA, Vincenti MP, Coon CI, et al. Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor kappaB: differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum 2000;43:801-811.
51. Liacini A, Sylvester J, Li WQ, et al. Inhibition of interleukin-1- stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-kappa B) transcription factors downregulates matrix metalloproteinase gene expression in articular chondrocytes. Matrix Biol 2002;21:251-262.
52. Caldenhoven E, Liden J, Wissink S, et al. Negative cross-talk between RelA and the glucocorticoid receptor: a possible mechanism for the antiinflammatory action of glucocorticoids. Mol Endocrinol 1995;9:401-412.
53. Scheinman RI, Gualberto A, Jewell CM, et al. Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors. Mol Cell Biol 1995;15:943-953.
54. Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of 1 kappa B synthesis. Science 1995;270:286-290.
55. Scheinman RI, Cogswell PC, Lofquist AK, et al. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 1995;270:283-286.
56. Patwari P, Gao G, Lee JH, et al. Analysis of ADAMTS4 and MT4-MMP indicates that both are involved in aggrecanolysis in interleukin-1-treated bovine cartilage. Osteoarthritis Cartilage 2005;13:269-277.
57. Caron JP, Tardif G, Martel-Pelletier J, et al. Modulation of matrix metalloprotease 13 (collagenase 3) gene expression in equine chondrocytes by interleukin 1 and corticosteroids. Am J Vet Res 1996;57:1631-1634.
58. Fubini SL, Todhunter RJ, Burton-Wurster N, et al. Corticosteroids alter the differentiated phenotype of articular chondrocytes. J Orthop Res 2001;19:688-695.
59. Pratta MA, Su JL, Leesnitzer MA, et al. Development and characterization of a highly specific and sensitive sandwich ELISA for detection of aggrecanase-generated aggrecan fragments. Osteoarthritis Cartilage 2006;14:702-713.
60. Tortorella MD, Pratta M, Liu RQ, et al. Sites of aggrecan cleavage by recombinant human aggrecanase-1 (ADAMTS-4). J Biol Chem 2000;275:18566-18573.
61. Tortorella MD, Liu RQ, Burn T, et al. Characterization of human aggrecanase 2 (ADAM-TS5): substrate specificity studies and comparison with aggrecanase 1 (ADAM-TS4). Matrix Biol 2002;21:499-511.
62. Barry FP, Rosenberg LC, Gaw JU, et al. N- and O-linked keratan sulfate on the hyaluronan binding region of aggrecan from mature and immature bovine cartilage. J Biol Chem 1995;270:20516-20524.